ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Growth in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 276,800 shares, a growth of 1,291.0% from the December 31st total of 19,900 shares. Approximately 11.8% of the company’s stock are short sold. Based on an average trading volume of 1,850,000 shares, the short-interest ratio is currently 0.1 days.

ZyVersa Therapeutics Stock Down 1.1 %

ZyVersa Therapeutics stock traded down $0.02 during midday trading on Thursday, reaching $1.36. 9,935 shares of the company traded hands, compared to its average volume of 2,210,845. ZyVersa Therapeutics has a 12 month low of $0.98 and a 12 month high of $25.00. The business has a 50 day moving average of $1.20 and a two-hundred day moving average of $2.10.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.